According to the accumulated data that identifies PLCγ1-downstream signaling as a major malignant mechanism in MF/SS, the clinical efficacy of targeting CaN using topical pimecrolimus is currently being addressed in a phase II clinical trial with patients at early stages (IA-IIA) of MF (PimTo-MF study, EudraCT 2014-001377-14). The gene discussed is PLCG1; the disease is mycosis fungoides.